MainboardGMP
LIVE
LIVE GMP
Watrana Rentals Ltd₹0·Crystal Crop Protection Ltd₹+45·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·M.K.Sons Fine Jewels Ltd₹+3·Watrana Rentals Ltd₹0·Crystal Crop Protection Ltd₹+45·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·M.K.Sons Fine Jewels Ltd₹+3·
Home › IPOs › Eris Lifesciences Ltd.
ER
Eris Lifesciences Ltd.
CLOSED NSE & BSE Bookbuilding IPO Offer For Sale Eris Lifesciences IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
₹603
Issue Price: ₹ 603
Issue Price
₹603
Face Value
₹1
Lot Size
24 shares
Open Date
16 Jun 2017
Close Date
20 Jun 2017
Allotment
23 Jun 2017
Listing Date
29 Jun 2017
Exchange
NSE & BSE
Eris Lifesciences IPO About the Company

Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.

Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.

Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).

In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.

Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.

Eris Lifescience Strengths:

• Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders
• Portfolio of high volume and leading brands
• Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and concentration of specialists and super specialists
• Multi-faceted product selection and engagement model leading to growth in prescription
• Strong sales, marketing and distribution capabilities

...read more
Eris Lifesciences IPO Objects of the Issue
Purpose Amount (₹ Cr)
1 The company will not receive any proceeds from the Offer and all the proceeds will go to the Selling Shareholders. —
Eris Lifesciences IPO Lead Managers
Axis Capital Ltd. Citigroup Global Markets India Pvt.Ltd. Credit Suisse Securities (India) Pvt.Ltd.
Financial Summary Amount In Crore
Metric 31-Mar-16 31-Mar-15 31-Mar-14
Total Assets 397 357 271
Revenue 597 546 509
PAT 135 89 71
Issue Details
Total Shares Offered
28,875,000 (100%)
Pre-Issue Shareholding
137,500,000 shares
Post-Issue Shareholding
137,500,000 shares
UPI Mandate
20 Jun 2017
IPO Analytics Dashboard
LIVE
Eris Lifesciences IPO GMP Insights
👤
Retail Demand
Weak
💼
HNI Interest
Good
🏦
QIB Demand
Strong
📊
Valuation
Moderate
Eris Lifesciences IPO GMP Strength Score
6 / 10 Moderate
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Eris Lifesciences IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB — 21,543,750 (75%) —
💼 NII / HNI — 4,308,750 (15%) —
👤 Retail (RII) — 2,872,500 (10%) —
🧑‍💼 Employee — 150,000 (1%) —
Σ Total — 28,875,000 (100%) —

* Amount calculated at upper price band (₹603) ·  ** Total includes all investor categories

Subscription Overview Share allocation by investor category
🏦
QIB ? 21,543,750 (75%)
75%
💼
NII / HNI ? 4,308,750 (15%)
15%
👤
Retail (RII) ? 2,872,500 (10%)
10%
🧑‍💼
Employee ? 150,000 (1%)
1%
Total Shares Offered 28,875,000 (100%)
Eris Lifesciences IPO Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 24
Min. Investment ₹14,472
💼 HNI Investors ?
Min. Lots 14
Min. Shares 336
Min. Investment ₹202,608
🏛️ bHNI (>₹10L) ?
Min. Lots 70
Min. Shares 1,680
Min. Investment ₹1,013,040
Eris Lifesciences IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 27 Jun 2017
  2. 2 📂 Credit of Shares to Demat 28 Jun 2017
  3. 3 🔒 Lock-in Period (30%) July 23, 2017
  4. 4 🔒 Lock-in Period (50%) September 21, 2017
Investor Interpretation
  • Retail allocation is weak at 10% of the total offering.
  • HNI/NII demand is good at 15%.
  • Institutional (QIB) interest is strong at 75%.

This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.

STOCK PRICE HISTORY  ·  NSE
—
Issue Price: ₹ 603  ·  Symbol: —
H —
L —
O —
Eris Lifesciences IPO Company Info
📍 7th Floor, Commerce House IV, Beside Shell Petrol Pump, 100 Feet Road, Prahladnagar, Ahmedabad 380 015 Ahmedabad, Gujarat
Visit Website
Eris Lifesciences IPO Registrar
MUFG Intime India Pvt.Ltd.
Check Allotment Status
Eris Lifesciences IPO FAQs
Eris Lifesciences IPO has already listed. Its last recorded GMP was ₹0. GMP is only indicative and never a guarantee of listing gains.
The issue price of Eris Lifesciences IPO is ₹603 per share. One lot has 24 shares, so the minimum investment is about ₹14,472. It is a Offer For Sale issue.
Eris Lifesciences IPO opened on 16 Jun 2017 and closed on 20 Jun 2017. Allotment is tentatively finalised on 23 Jun 2017. Shares are listed on NSE & BSE on 29 Jun 2017.
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
As per the offer document, Eris Lifesciences plans to use the IPO proceeds for: 1 The company will not receive any proceeds from the Offer and all the proceeds will go to the Selling Shareholders..
The lead managers of Eris Lifesciences IPO are Axis Capital Ltd., Citigroup Global Markets India Pvt.Ltd., Credit Suisse Securities (India) Pvt.Ltd..
Eris Lifesciences IPO is proposed to list on NSE & BSE; it is a Bookbuilding IPO and the issue is a Offer For Sale.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.